Viralgen specializes in the production of AAV gene therapy vectors using our proprietary suspension, triple transfection platform. This includes a HEK-293-derived suspension cell line, a scalable upstream and robust purification process, coupled with full support for fill and finish, QC testing, and regulatory support from preclinical to commercial requirements.

Contact Viralgen Vector Core
Visit Website